Defunct Company
Total Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
1,040
NCT00338507
Phase 2 Study - Erdosteine in Patients With CB/COPD
Phase: Phase 2
Role: Lead Sponsor
Start: Mar 31, 2006
Completion: Not specified
NCT00441246
Phase 4 Study - Mucinex D as Adjunct Therapy
Phase: Phase 4
Start: Feb 28, 2007
Completion: Jul 31, 2007
NCT05065645
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19
Phase: Phase 1
Role: Collaborator
Start: Oct 19, 2021
Completion: May 27, 2022